Core Equine Combination Vaccines: Top 5 Options in the UK for 2026
Published on Wednesday, 25 February 2026
Category: undefined — Core Equine Vaccines (Equine Health First Aid > Equine Vaccines Immunization Supplies > Core Equine Vaccines). This category focuses on multi-component, combination vaccines that protect horses against the fundamental infectious threats such as tetanus, equine influenza, and equine herpesvirus (EHV). In the UK market for 2026, British horse owners and equine practitioners increasingly recognise the value of combination formulations as a cornerstone of comprehensive herd-health management. Rather than giving several separate injections, veterinarians can administer a single dose that delivers protection against multiple pathogens. This streamlines yard protocols, reduces handling and stress for animals, minimises injection-site reactions, simplifies record-keeping for veterinary inspections, and improves owner compliance with vaccination schedules. Combination vaccines are particularly appealing to livery yards, stud farms, and private stables across the United Kingdom because they reduce labor and logistical burden while maintaining robust immunity when used according to veterinary guidance. Choice between products depends on risk assessment, discipline-specific exposure, availability through local distributors and equine pharmacies, and veterinary recommendation. This guide examines five leading combination vaccines available through UK distributors in 2026, comparing protective scope, formulation characteristics, practical suitability, and typical use cases.
Top Picks Summary
Equilis Prequenza Te
Included in the UK 2025 selection for its combined equine influenza plus tetanus formulation and a modern antigen update strategy that helps maintain strain relevance in high-risk populations. Compared with the other entries in this list, Equilis Prequenza Te balances influenza strain currency with a cost-effective dosing schedule that can reduce per-horse administration time and overall campaign costs, while fitting into the broader UK market context alongside well-known multivalents such as Vetera Gold XP and Prestige V + WNV.
Proteqflu-Te
A recombinant/vector-based influenza plus tetanus vaccine included for the 2025 UK guide because of its technical profile — including antigen stability and potential DIVA-compatible approaches — that can simplify outbreak investigations and herd management. Though unit cost may be higher than traditional inactivated multivalents like Equip EWT or Duvaxyn IE Plus, its platform can deliver downstream financial benefits by reducing outbreak-related losses and streamlining differential diagnostic workflows in the broader UK equine vaccine landscape.
Equip FT
Equip FT is presented as a best-in-class option for the use case "undefined" because it balances broad antigen coverage with a cost-effective dosing strategy, making it well suited to large-scale or budget-sensitive programs. Technically it is valued for straightforward handling and a lower per-dose price compared with the premium Equilis Resequin, while offering a more current antigen profile than the older Duvaxyn IE-T Plus.
Duvaxyn IE-T Plus
Duvaxyn IE-T Plus remains a market leader for the use case "undefined" thanks to its long commercial track record and wide availability, which often translates into reliable supply and competitive pricing. Financially it appeals to budget-conscious buyers and organizations prioritizing proven consistency, though it may not incorporate the newest adjuvant or antigen innovations found in Equilis Resequin or the expanded coverage emphasized by Equip FT.
Equilis Resequin
Equilis Resequin occupies a top-tier position for the use case "undefined" by offering an advanced formulation designed to boost immunogenic performance, a feature that can justify a higher upfront cost for purchasers seeking premium outcomes. Technically it can provide advantages in response or duration compared with Duvaxyn IE-T Plus, but typically commands a higher price than Equip FT, presenting a trade-off between enhanced performance and unit cost.
How combination core vaccines work and what the evidence says
Combination vaccines include antigens from multiple pathogens in a single preparation, often formulated with adjuvants to enhance and sustain immune responses. Scientific and regulatory evaluations focus on immunogenicity (ability to produce protective antibodies and cellular responses), safety (local and systemic reactions), and field effectiveness (reduction in clinical disease and outbreak control). In the UK and internationally, evidence from immunogenicity trials, field surveillance and pharmacovigilance supports the use of multi-component equine vaccines as an efficient approach to core disease prevention when integrated into a complete herd health plan developed with a veterinarian.
Immunogenicity studies: Controlled trials typically show that combination vaccines elicit protective antibody levels against included antigens comparable to single-antigen vaccines when administered following recommended schedules.
Reduced handling and adverse events: Fewer injections per visit lower handling stress and are associated with fewer injection-site reactions in field reports, improving horse welfare and owner compliance.
Field effectiveness and herd protection: Surveillance data from outbreaks and vaccination programs indicate that broad vaccination coverage with core products reduces the incidence and severity of equine influenza and tetanus cases.
Regulatory oversight and safety monitoring: UK safety reporting and regulatory review (for example by the Veterinary Medicines Directorate) track adverse events; licensed combination vaccines meet required safety and quality standards.
Practical guidance: Veterinary bodies and practice-level risk assessments guide product choice, scheduling, and booster intervals to manage maternal antibody interference in foals and to tailor protection for performance, breeding, and export requirements.
Conclusion
This review covered five leading multi-component core vaccines commonly used by UK yards in 2026: Equilis Prequenza Te, ProteqFlu-Te, Equip FT, Duvaxyn IE-T Plus, and Equilis Resequin. Each product has strengths depending on your yard's risk profile and logistical needs. For many UK situations the broad coverage and balanced formulation of Equilis Prequenza Te make it the best overall choice for combined core protection, while ProteqFlu-Te, Equip FT, Duvaxyn IE-T Plus, and Equilis Resequin remain excellent alternatives where specific antigen profiles, availability, or veterinary preference point to their use. We hope you found the information you were looking for. If you want to refine or expand your search, use the search function to filter by antigen coverage, formulation type, UK distributor availability, or veterinary recommendations.